The much-anticipated IPO for atai Life Sciences (US:ATAI) ended up being anti-climactic instead.
Novamind has just completed a strategic investment of US$1 million in a private psychedelics company, as part of a $25 million Series A financing.
Atai Life Sciences has re-filed with the SEC to increase its IPO financing from $100 to $246 million. It's a big deal.
Mydecine Innovations Group is a psychedelics company that The Dales Report has been watching closely this past year.
Co-Founder JR Rahn has stepped down as CEO of MindMed. His replacement, Robert Barrow, brings a wealth of clinical trials experience.